Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of moderate to high myopia (nearsightedness), when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.
Condition or disease
Device: MEL 80 Treatment of High Myopia
LASIK has become one of the most common refractive eye procedures performed in the country. Currently the MEL 80 Excimer Laser System is approved for the elimination of myopia of less than or equal to -7.0 D with or without refractive astigmatism of less than or equal to -3.0 D, with a maximum MRSE of -7.00 D. The goal of this study is to assess the safety and effectiveness information on the treatment of moderate to high magnitudes of myopia.
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
At the point of stability, for myopes > 7 D spherical equivalent (SE), a minimum of 30% should have an achieved refraction within ± 0.50 D of the intended outcome, and 60% should have an achieved refraction within ± 1.00 D of the intended outcome. [ Time Frame: Point of stability ]
For myopes > 7 D spherical equivalent (SE), a minimum of 75% of eyes should have an uncorrected visual acuity of 20/40 or better at the postoperative interval at which stability has been established. [ Time Frame: Point of stability ]
95% of eyes should have a change of < 1.00 D in manifest refraction spherical equivalent (MRSE) between 2 refractions performed at least 3 months apart, and the mean rate of MRSE change per month should be < 0.04 D. [ Time Frame: Point of stability ]
Distance BSCVA of worse than 20/40 at the postoperative interval at which stability has been established should occur in less than 1% of eyes that had a BSCVA of 20/20 or better before surgery. [ Time Frame: Point of stability ]
Loss of more than 2 lines of BSCVA should occur in less than 5% of eyes [ Time Frame: Point of stability ]
Less than 5% of eyes treated for sphere only should have a magnitude of postoperative manifest refractive astigmatism that varies from baseline cylinder by greater than 2.00 D at the postoperative interval at which stability has been established. [ Time Frame: Point of stability ]
Incidence of Adverse Events to occur in less than 1% of eyes [ Time Frame: Postopertive visits ]
Secondary Outcome Measures :
Subject Satisfaction: As measured by a subjective questionnaire, and will be considered as a secondary efficacy variable. [ Time Frame: Postoperative visits 3, 6, 9 and 12 months ]
Incidence of Complications [ Time Frame: Postoperative visits ]
Patient Symptoms: As measured by a subjective questionnaire, will be considered as a secondary safety variable [ Time Frame: Preoperative and Postoperative visits 3, 6, 9 and 12 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Myopia > -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane, with a maximum MRSE ≤-12.00 D.
Stable refraction for at least the last twelve months, as demonstrated by a change of less than 1.00 D of the spherical equivalent during the twelve months prior to the baseline examination of the eye to be treated, documented by previous clinical records.
Discontinue use of contact lenses at least 2 weeks for hard contacts and 3 days for soft lenses prior to the preoperative examination.
Hard contact lens wearers must have two central keratometry readings and two manifest refractions taken at least one week apart that do not differ by more than 0.50 D.
Visual acuity correctable to at least 20/40 in both eyes.
UCVA of 20/40 or worse in the operative eye.
At least 18 years of age.
Operative eye must be targeted for emmetropia.
Have a normal corneal topography.
Willing and able to return for scheduled follow up examinations for twelve months after surgery.
Sign and be given a copy of the written Informed Consent form.
History of anterior segment pathology, including cataracts (in the operative eye).
Clinically significant dry eye syndrome unresolved by treatment.
Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars within the ablation zone or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease.
Ophthalmoscopic signs of progressive or unstable myopia or keratoconus (or keratoconus suspect).
An ablation deeper than 250 microns from the corneal endothelium.
Irregular or unstable (distorted/not clear) corneal mires on central keratometry readings.
Blind in the fellow eye.
Undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of surgery for either refractive or therapeutic purposes.
History of ocular Herpes zoster or Herpes simplex keratitis.
History of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP >21 mm Hg.
Must not have diabetes, diagnosed autoimmune disease, connective tissue disease, or clinically significant atopic syndrome.
Must not be immunocompromised or use chronic systemic corticosteroid or other immunosuppressive therapy.
Patients must not be pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control.
Patients must not have a known sensitivity to planned study medications.
Patients must not be participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.
For Fellow (Second) Eyes in Simultaneous Bilateral Treatment Procedures
1. Flap complications during the first eye's surgery such as a free cap, partial flap, thin flap, or irregular flap.
2. Epithelial defect exceeding 2 mm x 2 mm in dimension, or clinically significant debris in the interface between the flap and underlying stroma for the first eye.
3. Severe blepharospasm in the first eye that may have prevented or impeded the completion of the keratectomy and/or the laser ablation procedure.
4. Poor subject cooperation with instructions for the first eye's surgery and/or poor subject fixation on the laser fixation target.
5. Aborted LASIK procedure in the first eye or PRK was performed in the first eye because LASIK was not possible.